NIFTYMID100 Archives - ChartAlert®

TATAELXSI – Q4 FY26 Earnings Call – 21-Apr-26

Tata Elxsi’s FY27 hinges on 8–9% growth from Transportation and Healthcare, with Media volatility. PBT margin expansion to 27% depends on utilization, fixed‑price delivery, and AI productivity; 100–150 bps risk from currency/salary cycles. Offshore leverage supports 24–26% EBITDA, but GenAI scalability remains unproven.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Healthcare deals close in Q1; Transportation grows high single-digit; Media & Comms stabilizes.
Outcome: Revenue grows 8–9%, led by Transportation (10–12%) and Healthcare recovery (5–7%). EBITDA margins expand to 25–26% on utilization gains and AI efficiencies. New verticals contribute <5% of revenue. Implication: In-line with guidance; margin trajectory supports valuation rerating.

TATAELXSI – Q4 FY26 Financial Results – 21-Apr-26

Tata Elxsi’s FY26 saw flat revenue and ~440 bps margin hit from cost inflation, with ~10% earnings decline in core verticals. Q4 rebound offers hope, but FY27 hinges on sustained topline recovery. Debt‑free, cash‑rich balance sheet limits downside, yet premium valuation demands earnings revival.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew a modest 0.76% YoY in FY26 (₹3,729 Cr → ₹3,757 Cr), signalling demand-side stagnation despite sequential recovery in Q4.
Q4FY26 revenue of ₹993.75 Cr grew 9.4% YoY and 4.2% QoQ — the strongest sequential print of the year, suggesting early-stage re-acceleration.
Other income remained a meaningful contributor at ₹184 Cr (FY26), reflecting treasury yield on the large cash/deposit base.

Bottomline

Reported PAT collapsed 20% YoY (₹784.94 Cr → ₹628.43 Cr) in FY26, heavily distorted by a ₹95.69 Cr exceptional item in Q3FY26.
Excluding the exceptional, pre-tax profit still declined ~10.4% YoY (₹1,028 Cr → ₹920.8 Cr), indicating genuine margin pressure independent of one-offs.
Q4FY26 PAT of ₹220.35 Cr grew 27.8% YoY and 102% QoQ — a strong recovery print that partially restores confidence.

Margins

EBITDA margin (pre-exceptional, ex-other income) compressed sharply: operating costs grew 4.9% while revenue was nearly flat, squeezing core profitability.
Employee costs as a percentage of revenue climbed to 58.1% in FY26 vs. 54.9% in FY25 — the primary margin headwind and key variable to watch.
Net profit margin contracted to 16.7% in FY26 from 21.1% in FY25 (on operating revenue basis), a ~440 bps deterioration.

Growth Trajectory

FY26 was a consolidation year: near-zero topline growth with double-digit cost inflation — a structurally concerning combination for a premium-valued IT services name.
Q4FY26 trajectory (revenue, PAT both inflecting upward YoY) offers a plausible base for FY27 recovery, contingent on demand visibility improving.
EPS fell from ₹126 to ₹100.89 YoY, eroding the earnings yield that justifies Tata Elxsi’s historically high PE multiples.

BIOCON – Q3 FY26 Earnings Call – 13-Feb-26

Topline growth hinges on GLP-1/biosimilar launch execution and insulin capacity scaling, while margins and cash flow depend on Syngene’s CRDMO recovery and debt reduction pace—model 12–18% revenue CAGR with 25–28% EBITDA as base, but skew risks to downside on regulatory delays.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Liraglutide/semaglutide launch in EU/Canada by late 2026; insulin capacity doubles on schedule, capturing 15–20% market share in interchangeable segments. Biosimilars grow 15–18% YoY (new launches offset legacy erosion); generics sustain 20%+ growth. Trigger: Regulatory clarity + successful tech transfers. Outcome: Group revenue grows 12–15% YoY; EBITDA margins expand to 26–28%.

RVNL – Q3 FY26 Earnings Call – 6-Feb-26

RVNL’s topline growth (10% CAGR) hinges on execution of INR 87,000 crore order book, but bottomline (7% EBITDA) and margins face structural pressure from bidding mix; FY26 profit stagnation likely, with FY27 recovery contingent on cost discipline and railway capex visibility.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) INR 40,000 crore railway works executed on time, (2) Bidding revenue scales to INR 10,000–12,000 crore/annum, (3) EBITDA margins stabilize at 7%.
Outcome: 10% topline growth, flat-to-low-single-digit profit growth in FY26; 12–15% profit growth in FY27 as margins recover. Stock trades at 15–18x P/E, supported by infrastructure capex tailwinds.

GLENMARK – Q3 FY26 Earnings Call – 2-Feb-26

GLENMARK’s topline hinges on Flovent/Monroe execution and RYALTRIS scale—12–20% growth bandwidth; bottomline leverages innovation margin uplift (23–28% EBITDA); margins rebound to 68–72% gross if respiratory/oncology launches deliver, but FX, litigation, and Monroe risks warrant 15–20% discount to consensus.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Flovent approved Q4 FY26; (2) Aumolertinib launches H2 FY27.

Topline: 12–15% consolidated revenue growth (India 18–20%, EM 15–18%). RYALTRIS hits $200M by FY28.
Bottomline: EBITDA margin expands to 25% (Flovent gross margin uplift, operating leverage). Net cash ~INR 800Cr.
Margins: Gross margin recovers to 68–70% (respiratory mix shift).

KEI – Q3 FY26 Earnings Call – 22-Jan-26

KEI’s topline hinges on Sanand execution (INR6,000 crore swing) and export scalability (20% mix), while margins depend on copper pass-through (10–15% pricing power) and EHV mix (25% share)—11% EBITDA achievable if risks are managed, but downside skews to execution delays and commodity cycles.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Sanand on track + copper stable (LME $9,000) + export 20%.

Topline: INR11,000 crore (18% growth) with Sanand contributing INR2,700 crore.
EBITDA Margin: 11.2% (export mix + EHV ramp).
Implication: 20% CAGR validated; ROCE 15%+ by FY29.

OBEROIRLTY – Q3 FY26 Earnings Call – 20-Jan-26

OBEROIRLTY’s FY26 topline growth hinges on launch execution (50% probability of partial slippage), while FY27’s “big year” thesis requires flawless RERA/commencement timelines; margins are structurally supported by premium pricing but vulnerable to absorption risks in Goregaon/Borivali, and FCF inflection is deferred to FY27 pending land monetization.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) 50% of Q4 FY26 launches execute (Goregaon, Borivali, but NCR slips); (2) Premium demand holds (Rs. 50,000+/sq. ft. sales at 70% of inventory); (3) Sky City leasing hits 80% by FY26-end.
Outcome: Revenue growth 15–20% YoY in FY27 (spillover effect), margins stable (±50 bps) on pricing power; FCF breakeven by H2 FY27 as land spends monetize. Thane’s mixed-use projects gain traction, adding Rs. 1,500 crore to pipeline.

TATACOMM – Q3 FY26 Earnings Call – 21-Jan-26

TATACOMM’s topline: 8–12% CAGR feasible if digital (15% YoY) offsets core cyclicality (3–5% YoY); Bottomline: EBITDA margin expansion to 22–25% hinges on AI/SaaS execution and cost discipline; Margins: Structural upside in cloud/security (18.9% YoY) and CIS (post-contract exits), but media/MOVE drag persists.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: (1) Commotion pilots convert to revenue (10% digital growth by FY27); (2) Core connectivity stabilizes (3–4% YoY growth).
Outcome: Digital breakeven by FY27; EBITDA margins expand to 22% by FY28. Revenue CAGR of 8–10%, driven by cloud/security (18.9% YoY) and next-gen connectivity (17% YoY). FCF: INR 1,200–1,500 Cr annualized post-FY26.

TATAELXSI – Q3 FY26 Earnings Call – 13-Jan-26

TATAELXSI: Transportation-led growth (5–7%) depends on OEM spend; Media/Healthcare recovery vital for 8–10%+. EBITDA expansion (24–26%) hinges on utilization/cost discipline, but vertical concentration and cyclicality remain risks. Margins could reach 26–27% in bull case, tempered by Media/Healthcare execution and defense receivable challenges.

1–2 minutes

3-Scenario Framework

📊 Base Case (50% Probability)

Transportation grows mid-single digits, Media/Healthcare recover in Q4, and utilization hits 80%. EBITDA expands to 24–25% by FY27 on operating leverage. Defense/aerospace contributes 2–3% of revenue with neutral ROCE. Key variables: (1) Q4 deal wins, (2) hiring calibration. Outcome: Revenue growth 7–9% YoY; margins stabilize at 23–25%.